Summary

The 7 major encephalitis markets reached a value of US$ 15.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 23.4 Billion by 2034, exhibiting a growth rate (CAGR) of 4.1% during 2024-2034.

The encephalitis market has been comprehensively analyzed in IMARC's new report titled "Encephalitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Encephalitis refers to a rare yet serious ailment in which the brain becomes inflamed. The symptoms can vary widely, often starting off with flu-like signs, such as fever, headache, fatigue, muscle or joint pain, generally feeling unwell, etc. As the condition progresses, more severe indications may emerge, including confusion or disorientation, seizures, changes in personality or behavior, headaches, sudden high fever, hallucinations, speech or hearing problems, loss of consciousness, difficulties with movement or sensation, etc. In extreme cases, encephalitis may lead to life-threatening complications such as respiratory arrest, coma, or brain damage. The diagnosis of encephalitis consists of a detailed medical history and physical examination, with the doctor looking for signs of brain inflammation. This can be followed by specific diagnostic tests like a lumbar puncture (spinal tap) to analyze the cerebrospinal fluid for indications of infection or inflammation. Various neuroimaging techniques, including magnetic resonance imaging (MRI), are often used to visualize brain structures and detect any swelling or abnormalities. Additionally, blood tests are utilized to identify potential infectious agents or immune responses.

The increasing cases of infections caused by several viruses, such as Herpes Simplex Virus (HSV), Varicella-Zoster Virus (VZV), West Nile virus (WNV), tick-borne viruses, enteroviruses, etc., which directly infect the brain and cause inflammation, are primarily driving the encephalitis market. Furthermore, the escalating usage of anticonvulsant medications, including phenytoin and levetiracetam, for controlling seizures and preventing their recurrence is also bolstering the market growth. Apart from this, the emerging popularity of neuroprotective drugs that target specific pathways involved in neuronal injury and inflammation to preserve brain function as well as promote recovery is acting as another significant growth-inducing factor. Additionally, numerous key players are investing in R&D activities to develop antiviral therapies that aim to inhibit viral replication and reduce the duration and severity of the infection. This, in turn, is further creating a positive outlook for the market. Moreover, the introduction of advanced imaging techniques, such as diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR), which provide detailed visualization of brain abnormalities, including inflammation, edema, lesions, etc., is expected to drive the encephalitis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the encephalitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for encephalitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the encephalitis market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the encephalitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the encephalitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current encephalitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the encephalitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the encephalitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the encephalitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of encephalitis across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of encephalitis by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of encephalitis by gender across the seven major markets?
How many patients are diagnosed (​2018-2034​) with encephalitis across the seven major markets?
What is the size of the encephalitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of encephalitis?
What will be the growth rate of patients across the seven major markets?

Encephalitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for encephalitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the encephalitis market?
What are the key regulatory events related to the encephalitis market?
What is the structure of clinical trial landscape by status related to the encephalitis market?
What is the structure of clinical trial landscape by phase related to the encephalitis market?
What is the structure of clinical trial landscape by route of administration related to the encephalitis market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Encephalitis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Encephalitis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Encephalitis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)

8 Encephalitis - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Encephalitis - Unmet Needs

10 Encephalitis - Key Endpoints of Treatment

11 Encephalitis - Marketed Products
11.1 List of Encephalitis Marketed Drugs Across the Top 7 Markets
11.1.1 Ixiaro (Japanese Encephalitis Vaccine) - Valneva
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 TicoVac (Tick-borne encephalitis vaccine) - Hyland Immuno/Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Encephalitis - Pipeline Drugs
12.1 List of Encephalitis Pipeline Drugs Across the Top 7 Markets
12.1.1 NPB-01 - Nihon Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Satralizumab - Chugai Pharmaceuticals/Roche
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Rozanolixizumab - UCB
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Encephalitis - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Encephalitis – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Encephalitis - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Encephalitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Encephalitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Encephalitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Encephalitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Encephalitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Encephalitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Encephalitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Encephalitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Encephalitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Encephalitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Encephalitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Encephalitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Encephalitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Encephalitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Encephalitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Encephalitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Encephalitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Encephalitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Encephalitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Encephalitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Encephalitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Encephalitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Encephalitis - Access and Reimbursement Overview

16 Encephalitis - Recent Events and Inputs From Key Opinion Leaders

17 Encephalitis Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Encephalitis Market – Strategic Recommendations

19 Appendix